Month: July 2020

NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF) today reported financial results for the second quarter of 2020.During the second quarter of 2020, we experienced a partial recovery of our AUM which was adversely impacted by severe market declines arising from the COVID-19 pandemic toward the end of the prior quarter.  This recovery was driven principally by market appreciation, resulting in a 14.6% increase of our ending AUM.  Our business continues to operate remotely without disruption.$23.0 million of non-cash charges, including (i) a loss on revaluation of deferred consideration of ($23.4) million (ii) a loss on extinguishment of debt of ($2.4) million and (iii) a release of a deferred tax valuation allowance of $2.8 million.($13.3) million net loss ($8.51 million net income, as adjusted),...

MIDDLETOWN, R.I., July 31, 2020 (GLOBE NEWSWIRE) — KVH Industries, Inc. (Nasdaq: KVHI) reported financial results for the quarter ended June 30, 2020 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company’s website.Second Quarter 2020 HighlightsTotal revenues from continuing operations were $36.9 million compared to $39.7 million in the second quarter of 2019, a 7% decline. Revenues for AgilePlans, our Connectivity as a Service program for the commercial maritime sector, were up more than 72% compared to the second quarter of 2019. AgilePlans, amounted to 72% of total commercial maritime mini-VSAT Broadband shipments, and 60% of the total mini-VSAT Broadband shipments...

NEW HAMPTON, N.Y., July 31, 2020 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) reported today record second quarter net earnings of $21.1 million for 2020, compared to net earnings of $19.8 million for the second quarter 2019.  Record second quarter adjusted net earnings(a) were $27.6 million, compared to $25.2 million in the prior year quarter, and adjusted EBITDA(a) was an all-time record of $43.9 million, compared to $40.0 million in the prior year quarter.Second Quarter 2020 Financial Highlights:Net sales of $173.4 million, an increase of $11.8 million, or 7.3%, compared to the prior year quarter, with year over year sales growth in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.GAAP net earnings were $21.1 million, an increase of $1.3 million, or 6.5% from the prior year. These net earnings...

LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on August 5, 2020 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2020.Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.Date: August 5, 2020Time: 4:30 PM Eastern TimeParticipant Dial-in: 212-231-2931A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available for approximately one week by calling 412-317-6671...

ATHENS, Greece, July 31, 2020 (GLOBE NEWSWIRE) — Capital Product Partners L.P. (the “Partnership”, “CPLP” or “we” / “us”) (NASDAQ: CPLP), an international owner of ocean-going vessels, today released its financial results for the second quarter ended June 30, 2020.HighlightsQuarterly Revenues, Expenses and Net Income of $36.6 million, $22.7 million and $8.7 million respectively for the second quarter of 2020.Operating Surplus1 and Operating Surplus after the quarterly allocation to the capital reserve of $25.5 million and $16.2 million respectively.Successfully completed the refinancing of three 9,000 TEU container vessels.Extended period charters for three of our vessels and secured new employment for either the M/V ‘Adonis’ or the M/V ‘Akadimos’.Announced common unit distribution of $0.10 for the second quarter of 2020 and revised...

GEORGE TOWN, Grand Cayman, July 31, 2020 (GLOBE NEWSWIRE) —Operational and Strategic Highlights:Q2 2020 revenue was 17.3 Million, up 21.1% from the same quarter in the previous year and up 10.9% sequentially and within the range of guidance provided on May 8th, 2020.GAAP net income per fully diluted ADS in the second quarter of 2020 was 1 cent, with non-GAAP net income of 3 cents per fully diluted ADS.O2Micro expects the Q3 2020 revenue to be $17.6 million to $19.0 million compared to $16.0 million in the comparable quarter of the previous year.              O2Micro® International Limited (NASDAQ: OIIM), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, reported its financial results today for the Second quarter ending June 30, 2020.Financial Highlights for the Second...

New Drug Application (NDA) and Marketing Authorization Application (MAA) Submissions for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for the Second Half of 2020Phase 3 DERBY and OAKS Trials Evaluating Pegcetacoplan in Geographic Atrophy (GA) Fully Enrolled; Top-line Data Expected in the Third Quarter of 2021PRINCE Trial Evaluating Pegcetacoplan in Treatment-Naïve PNH Patients Fully Enrolled; Top-line Data Expected in the First Half of 2021Cash and Investments of $833 Million as of June 30, 2020WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2020 financial results and business highlights.“This past quarter, Apellis continued to make remarkable progress advancing...